Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00404989
Recruitment Status : Recruiting
First Posted : November 29, 2006
Last Update Posted : July 6, 2017
Apotex Inc.
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Hoffmann-La Roche
Gilead Sciences
Hetero Labs Ltd.
Janssen Scientific Affairs
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis Pharmaceuticals
Prinston Pharmaceutical Inc.
Ranbaxy Inc., a SunPharma Co.
Sciegen Pharmaceuticals Inc.
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Shasun Ltd.
Teva Pharmaceuticals USA
ViiV Healthcare
Alvogen Korea
Amneal Pharmaceuticals, LLC
West-Ward Pharmaceutical
Dr. Reddy's Laboratories UK Ltd.
Zentiva Group
Information provided by (Responsible Party):
INC Research

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 2099
  Estimated Study Completion Date : January 2099